Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Endoscopic scoring system for ulcerative colitis severity. Validated for assessing mucosal disease activity during colonoscopy.
Score interpretation
UCEIS 0–1 — mucosal remission
→ Maintain current therapy; consider step-down if in sustained remission
UCEIS 2–4 — mild to moderate endoscopic activity
→ Optimise 5-ASA or initiate/increase immunosuppressive therapy; repeat endoscopy at 3–6 months
UCEIS 5–8 — severe endoscopic activity
→ Biologic therapy (infliximab/vedolizumab) or intensification; surgical consultation if failing medical therapy
Interpretation bands for the UCEIS. Apply clinical judgement and local guidance.
References
- Travis SP et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(5):987–995.
Related
Curated clinical cross-links plus same-class fallbacks.
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Crohn's Disease Activity Index (CDAI) · Inflammatory Bowel Disease
- Truelove and Witts Severity Index for Ulcerative Colitis · Inflammatory Bowel Disease
- Simplified Endoscopic Score for Crohn's Disease (SES-CD) · Inflammatory Bowel Disease
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
- Dapsone · Anti-inflammatory / Antimicrobial
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Colchicine · Anti-inflammatory — Neutrophilic Dermatoses / Vasculitis
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Diclofenac · Non-Steroidal Anti-Inflammatory Drug (NSAID)
- Colchicine (Acute Gout) · Anti-Inflammatory (Microtubule Inhibitor)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.